Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
9(64%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
9
64%
Ph phase_2
5
36%

Phase Distribution

9

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
9(64.3%)
Phase 2Efficacy & side effects
5(35.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

14

all time

Status Distribution
Active(10)
Completed(3)
Other(1)

Detailed Status

Recruiting9
Completed3
Suspended1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
9
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (64.3%)
Phase 25 (35.7%)

Trials by Status

suspended17%
recruiting964%
completed321%
not_yet_recruiting17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT06876142Phase 1

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Suspended
NCT05983159Phase 2

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

Recruiting
NCT07061951Phase 2

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Recruiting
NCT07539441Phase 1

A Study of Mirdametinib in People With Central Nervous System Tumors

Recruiting
NCT06159166Phase 1

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

Recruiting
NCT07521657Phase 2

Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

Not Yet Recruiting
NCT07279233Phase 1

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Completed
NCT06843967Phase 1

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Recruiting
NCT06666348Phase 1

Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

Recruiting
NCT04923126Phase 1

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Recruiting
NCT03905148Phase 1

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Completed
NCT07237100Phase 2

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Recruiting
NCT06153173Phase 2

Mirdametinib in Histiocytic Disorders

Recruiting
NCT05054374Phase 1

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14